

The Parasitic Fingerprint: Tracing Infection to Host Illness

Shubham Sah^{1,*}, Deepa Kumari²

Abstract

Parasitic infections remain a major global health burden, causing significant morbidity and mortality, particularly in tropical and subtropical regions. A critical aspect of disease pathogenesis is the unique molecular and cellular imprint left by parasites in their hosts, termed the “parasitic fingerprint.” These fingerprints encompass parasite-derived proteins, nucleic acids, metabolites, extracellular vesicles, and host responses, including gene expression changes, cytokine profiles, and metabolic adaptations. Advances in multi-omics technologies, which integrate genomics, transcriptomics, proteomics, metabolomics, and epigenomics, have enabled high-resolution mapping of host–parasite interactions, revealing strategies parasites employ to invade, survive, and manipulate host systems. Molecular fingerprints offer clinical relevance by providing sensitive diagnostic markers, informing disease prognosis, guiding vaccine design, and enabling targeted therapeutic interventions. Case studies in malaria, leishmaniasis, trypanosomiasis, and helminth infections demonstrate the utility of fingerprints in linking parasite activity to tissue-specific pathology and host immune modulation. Integration of these insights into emerging technologies, such as single-cell multi-omics, spatial transcriptomics, and artificial intelligence, holds promise for personalized medicine approaches, improving disease management and reducing the global burden of parasitic diseases.

Keywords: Parasitic fingerprint, host-parasite interactions, multi-omics, diagnostics, therapeutics, malaria, leishmaniasis, trypanosomiasis, helminths, precision medicine

INTRODUCTION

Parasitic diseases remain a major global health challenge, affecting millions of people and causing substantial morbidity and mortality, particularly in tropical and subtropical regions. Parasites, including protozoa, helminths, and ectoparasites, have evolved complex life cycles and sophisticated strategies to invade, survive, and propagate within their hosts [1]. These infections are often chronic, leading to long-term complications that affect organs, tissues, and the host immune system. Despite advances in therapeutics and control measures, parasitic diseases continue to impose a heavy clinical and socioeconomic burden, particularly in resource-limited settings. A fundamental aspect of parasitic disease pathogenesis is the molecular and cellular imprint that parasites leave on their hosts, which can be described as the “parasitic fingerprint.” This concept encompasses the unique biochemical, proteomic, genomic, and immunological signatures generated during infection, which not only facilitate parasite survival but also influence disease severity and clinical outcomes. Understanding these fingerprints is crucial for elucidating the mechanisms of disease progression, identifying potential biomarkers, and developing targeted therapeutic strategies [2]. Host–parasite interactions are dynamic and multifaceted. Upon infection, parasites encounter the host immune system and other cellular defences, triggering a cascade of

*Author for Correspondence

Shubham Sah
E-mail: shubham24@iisertvm.ac.in

¹Student, Department of Biological Science, Indian Institute of Science Education and Research, Thiruvananthapuram, Kerala, India

²Student, Department of Biochemistry, Central University of Haryana, Mahendergarh, Haryana, India

Received Date: February 04, 2026

Accepted Date: February 05, 2026

Published Date: February 20, 2026

Citation: Shubham Sah, Deepa Kumari. The Parasitic Fingerprint: Tracing Infection to Host Illness. Recent Trends in Infectious Diseases. 2026; 3(1): 29–50p.

molecular events. While hosts mount innate and adaptive immune responses to eliminate or control the invading parasite, parasites simultaneously deploy evasion strategies, such as antigenic variation, molecular mimicry, and immune modulation, to avoid clearance [3]. These interactions leave discernible molecular traces in host tissues, blood, and other biological fluids, forming the basis of the parasitic fingerprint. Recent advances in multi-omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, have enabled high-resolution mapping of host-parasite interactions, providing unprecedented insight into disease mechanisms. Furthermore, the integration of molecular fingerprints with clinical phenotypes offers new opportunities for developing sensitive diagnostics, predictive biomarkers, and precision therapeutics. This review comprehensively explores the concept of the parasitic fingerprint, tracing the journey from infection to host illness [4]. The molecular signatures generated during parasitic infections, the mechanisms underlying host pathology, and the implications for diagnostics, therapeutics, and disease control are examined. By bridging the gap between parasite biology and clinical outcomes, this synthesis provides a framework for understanding the complex interplay between parasites and their hosts and highlights future directions for research and translational applications [5].

HOST-PARASITE INTERACTIONS

Understanding host–parasite interactions is central to tracing the molecular and pathological fingerprints that define parasitic diseases. These interactions are dynamic, multifaceted, and occur across molecular, cellular, and systemic levels. Parasites must overcome numerous host defences to establish infection, while hosts employ innate and adaptive mechanisms to control or eliminate the invader. The outcome of this evolutionary arms race shapes the clinical manifestations, tissue pathology, and long-term consequences of parasitic infections [6].

Entry and Invasion

Parasites utilize diverse strategies to enter the host, dictated by their life cycle and ecological niche. Protozoan parasites, such as *Plasmodium spp.*, *Leishmania spp.*, and *Trypanosoma spp.*, often enter through vectors or contaminated fluids, whereas helminths may penetrate the skin or gastrointestinal tract. Successful invasion depends on the parasite's ability to recognize host receptors and adhere to specific cell types. For example, *Plasmodium falciparum* merozoites exploit erythrocyte surface receptors, including glycophorin A, to invade red blood cells, while *Leishmania* promastigotes interact with macrophage receptors, such as complement receptor 3 (CR3) and mannose receptor, to gain intracellular entry. Parasites secrete specialized effector proteins and enzymes that facilitate penetration of host barriers. Proteases, lipases, and adhesion molecules remodel host membranes and extracellular matrices, promoting parasite entry and dissemination. Some parasites induce endocytosis or phagocytosis, while others actively traverse cell junctions. This precise orchestration of molecular mechanisms leaves identifiable footprints in host tissues, forming the basis of early parasitic fingerprints (Figure 1) [7–10].

Host Immune Recognition

The host immune system is the first line of defence against parasitic invasion. Innate immunity involves physical barriers, complement activation, phagocytic cells, and pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs). Toll-like receptors (TLRs), C-type lectin receptors, and nucleotide-binding oligomerization domain (NOD)-like receptors play key roles in sensing parasites and initiating inflammatory responses [11, 12]. For instance, *Trypanosoma cruzi* glycosylphosphatidylinositol anchors activate TLR2 and TLR4 pathways, triggering cytokine release and oxidative responses. Adaptive immunity provides specificity and memory through T and B lymphocytes. CD4⁺ T helper cells orchestrate immune responses by differentiating into Th1, Th2, or Th17 subsets, each promoting distinct effector mechanisms [13]. Th1-mediated interferon- γ production is crucial for controlling intracellular parasites, such as *Leishmania*, while Th2 responses drive eosinophilia and antibody-mediated immunity against helminths. B cells produce parasite-specific antibodies that neutralize antigens, opsonize pathogens, or activate complement pathways. These immune interactions generate detectable molecular patterns that contribute to the parasitic fingerprint.




Figure 1. Metabolomics as a systems immunology tool for profiling host responses during parasitic infection. This figure illustrates how metabolomic approaches integrate with systems immunology to distinguish between infected and non-infected as well as vaccinated and non-vaccinated states. It highlights the identification of targeted metabolic signatures and pathways alongside immune response readouts, enabling comprehensive analysis of host–parasite interactions.

Source: https://www.mdpi.com/metabolites/metabolites-10-00492/article_deploy/html/images/metabolites-10-00492-g001.png

Immune Evasion by Parasites

To persist within hosts, parasites employ sophisticated evasion strategies that modulate or escape immune responses. Antigenic variation, a hallmark of *Trypanosoma brucei*, allows parasites to periodically change surface glycoproteins, evading antibody recognition [14, 15]. Molecular mimicry enables parasites to express host-like molecules, reducing immune detection. Other parasites secrete immunomodulatory proteins that inhibit antigen presentation, block complement activation, or induce regulatory T cell expansion, thereby dampening host immunity. Helminths are particularly adept at immune modulation, releasing excretory–secretory products that skew host immunity toward anti-inflammatory Th2 responses. This not only facilitates chronic infection but also leaves a lasting immunological imprint that can be traced as part of the parasitic fingerprint. These evasion mechanisms highlight the dynamic interplay between host defenses and parasite survival strategies [16–20].

Cellular and Tissue Tropism

Different parasites exhibit tropism for specific host tissues, shaping the clinical manifestations and molecular fingerprints of infection. *Plasmodium* species target erythrocytes and hepatocytes, leading to anemia, hepatosplenomegaly, and systemic inflammation. *Leishmania* species infect macrophages in

the skin, liver, and spleen, causing cutaneous or visceral lesions. Tissue tropism determines localized cytokine profiles, cellular damage, and host metabolic alterations, all of which contribute to disease-specific molecular signatures. Within target tissues, parasites can trigger apoptosis, necrosis, or altered cellular signaling. For example, *Toxoplasma gondii* modulates host gene expression to suppress apoptosis in infected cells, facilitating intracellular replication. Helminths induce fibrosis, angiogenesis, and immune cell infiltration in the gut or liver, generating distinct histopathological and molecular markers. Understanding these tissue-specific footprints is critical for linking parasite invasion to host illness [21–25].

Host–Parasite Molecular Interplay

The interaction between host and parasite is not merely antagonistic; it is a dynamic molecular dialogue. Parasites manipulate host signaling pathways, metabolic networks, and gene expression to create a permissive environment for survival. For instance, *Plasmodium falciparum* remodels erythrocyte membranes by exporting proteins, such as PfEMP1, altering adhesion and immune recognition. Similarly, *Leishmania* secretes GP63 protease to degrade host signaling proteins, impairing macrophage activation. Host cells respond by activating stress pathways, inflammatory mediators, and cell death mechanisms, leaving detectable molecular traces. These interactions form the core of the parasitic fingerprint, which can be identified through proteomic, transcriptomic, or metabolomic profiling. High-resolution mapping of these interactions allows researchers to trace the molecular trajectory from infection to tissue pathology and disease outcomes [25, 26].

MOLECULAR SIGNATURES OF INFECTION

Parasitic infections leave discernible molecular imprints in their hosts, collectively referred to as the “parasitic fingerprint.” These signatures encompass alterations in host proteins, gene expression, metabolites, and extracellular factors induced by the invading parasite. Understanding these molecular changes provides insights into parasite survival strategies, disease pathogenesis, and potential diagnostic and therapeutic avenues (Figure 2) [27–30].

Proteomic Fingerprints

Proteomic profiling has revealed that parasites introduce unique proteins into host tissues and fluids, which can serve as direct indicators of infection. For example, *Plasmodium falciparum* exports numerous erythrocyte membrane proteins, such as PfEMP1, RIFINs, and STEVORs, that remodel the host cell surface and mediate cytoadherence, immune evasion, and pathogenicity [31–35]. These exported proteins generate measurable alterations in host blood composition and cell membrane architecture, forming identifiable proteomic fingerprints [36]. Similarly, *Leishmania* species secrete proteins, like GP63 and lipophosphoglycan (LPG) into macrophages, modulating immune signaling and enabling parasite survival. Proteomic analysis of infected tissues reveals differential expressions of host proteins involved in antigen processing, signal transduction, and apoptosis [37]. Helminth infections also induce protein expression changes in the host, often linked to tissue remodeling, fibrosis, and immune regulation. Identifying these protein-level changes is crucial for tracing infections and predicting disease outcomes.

Genomic and Epigenomic Changes

Parasites influence host gene expression through direct and indirect mechanisms. Intracellular parasites, such as *Toxoplasma gondii* and *Plasmodium spp.*, manipulate host transcriptional machinery to suppress apoptosis, modulate inflammatory responses, and enhance nutrient availability. Host transcriptomic analyses of infected cells often reveal upregulation of stress response genes, pro-inflammatory cytokines, and interferon-stimulated genes [38–40]. Conversely, genes involved in antigen presentation, cell cycle regulation, or metabolic homeostasis may be downregulated, reflecting parasite-driven modulation. Epigenetic modifications, including DNA methylation and histone modifications, further contribute to the molecular fingerprint. For instance, *Toxoplasma* infection can induce host histone modifications that alter chromatin accessibility and gene expression patterns, promoting long-term changes in immune responsiveness. Such genomic and epigenomic alterations

provide a molecular map connecting parasite presence to host pathology and are increasingly explored as biomarkers for infection severity and chronicity [41].




Figure 2. Molecular signatures of parasitic infection across multi-omics platforms. This figure represents the diverse molecular fingerprints generated during parasitic infections, including proteomic, genomic, transcriptomic, and metabolomic alterations. It emphasizes how these interconnected layers contribute to understanding parasite survival strategies, host immune modulation, and disease progression.

Source: <https://www.intechopen.com/media/chapter/56631/media/F2.png>

Metabolomic and Biochemical Markers

Parasitic infections also perturb host metabolism, creating distinct metabolomic signatures. In malaria, *Plasmodium*-infected erythrocytes consume glucose at high rates, leading to hypoglycaemia and altered plasma metabolite profiles. Amino acid depletion, lipid remodeling, and accumulation of parasite-derived metabolites, such as hemozoin, contribute to both host pathology and molecular fingerprints detectable through metabolomics [42–45]. Helminth infections, particularly chronic gastrointestinal infestations, modulate host lipid, carbohydrate, and vitamin metabolism, reflecting both parasite nutrient acquisition and host immune adaptation. Alterations in metabolites, like short-chain fatty acids, polyamines, and nitric oxide derivatives, can serve as indicators of infection and disease progression. Integrating metabolomic data with proteomic and genomic information provides a multi-dimensional view of the parasitic fingerprint, enabling a holistic understanding of host–parasite interactions [46–48].

Extracellular Vesicles and Secreted Factors

Parasites actively communicate with host cells via extracellular vesicles (EVs) and secreted molecules. EVs carry proteins, RNAs, microRNAs, and lipids that modulate host immune responses,

cellular signaling, and gene expression. For example, *Leishmania* exosomes deliver GP63 and small RNAs to host macrophages, suppressing pro-inflammatory cytokines and altering transcriptional programs. *Plasmodium*-derived microvesicles influence endothelial cell activation and vascular inflammation, contributing to cerebral malaria pathogenesis [49–52]. Secreted factors, such as proteases, lipids, and glycoproteins, similarly manipulate host signaling pathways, promoting immune evasion and tissue remodeling. These vesicles and secreted molecules leave measurable molecular footprints that can be detected in blood, urine, or tissue biopsies, making them valuable biomarkers for infection and disease monitoring [53].

Integration of Molecular Signatures

The parasitic fingerprint is best understood by integrating multiple molecular layers. Proteomic, transcriptomic, metabolomic, and secretomic data collectively provide a detailed map of host responses and parasite activity [54–59]. Multi-omics approaches enable researchers to identify critical nodes in host-parasite interactions, predict disease severity, and discover novel diagnostic markers. For instance, combining proteomic data of exported parasite proteins with host transcriptomic changes can reveal pathways essential for immune evasion and tissue damage, highlighting targets for therapeutic intervention [60]. Recent advances in computational biology, machine learning, and systems biology facilitate the integration of large-scale molecular data. Predictive models can correlate specific molecular signatures with clinical outcomes such as organ damage, anemia, or neurological complications in malaria, or tissue fibrosis in helminth infections [61, 62]. These approaches not only enhance our understanding of disease mechanisms but also allow for personalized diagnostics and targeted treatment strategies based on the molecular fingerprint of infection.

DISEASE MECHANISMS AND PATHOLOGY

The molecular fingerprints left by parasites in the host are intricately linked to the mechanisms of disease and pathology observed during infection [63–65]. Parasites induce host tissue damage through a combination of direct cellular injury, immunopathological responses, and long-term organ remodeling. Understanding these processes is crucial for connecting infection to the manifestation of illness and interpreting the clinical consequences of parasitic diseases [66–70].

Direct Tissue Damage

Parasites cause direct damage to host tissues through physical disruption, cytolysis, and nutrient depletion [71–73]. Protozoan parasites, like *Plasmodium falciparum*, invade red blood cells (RBCs) and undergo repeated cycles of replication and lysis, leading to hemolysis, anemia, and microvascular obstruction. Similarly, *Trypanosoma cruzi* invades cardiac myocytes, replicates intracellularly, and triggers cell rupture, resulting in myocarditis and chronic cardiomyopathy [74, 75]. Helminths, by contrast, inflict mechanical damage during migration through tissues. Schistosome larvae penetrate the skin, travel through the bloodstream, and lodge in the liver or intestines, causing granulomatous inflammation and fibrosis. Larval migration by *Ascaris lumbricoides* through the lungs can result in tissue hemorrhage and eosinophilic inflammation [76–80]. These forms of direct tissue injury leave molecular footprints, including cellular debris, altered extracellular matrix components, and the presence of parasite-derived antigens, which can be detected through histopathological and molecular assays.

Immunopathology

Host immune responses, while protective, can contribute to disease through immunopathological mechanisms. The inflammatory response to parasitic infection often generates tissue damage in addition to parasite clearance [81, 82]. Cytokines, such as interferon- γ (IFN- γ), tumor necrosis factor- α (TNF- α), and interleukins (IL-1 β , IL-6), are released in response to infection, activating macrophages, neutrophils, and other immune cells. While these mediators limit parasite proliferation, excessive or dysregulated responses can damage host tissues. For instance, cerebral malaria is associated with overactivation of endothelial cells and sequestration of infected RBCs, mediated by parasite proteins like PfEMP1 and host inflammatory cytokines [83–85]. The resulting blood-brain

barrier disruption, edema, and microvascular obstruction are hallmarks of severe immunopathology. Similarly, visceral leishmaniasis induces splenomegaly and hepatomegaly through excessive macrophage activation and chronic inflammatory signaling. Helminth-induced Th2 responses, while controlling worm burden, can lead to tissue fibrosis, airway hyperreactivity, or gut hypertrophy. These immunopathological events are reflected in molecular and cellular fingerprints that can serve as biomarkers for disease severity [86–90].

Malaria
(*Plasmodium* spp.)




Figure 3. Life cycle of *Plasmodium* species and stages of malaria infection in human and mosquito hosts. This diagram depicts the complete life cycle of *Plasmodium* spp., including the mosquito (sporogonic) and human (exo-erythrocytic and erythrocytic) stages. It highlights key infective and diagnostic stages, illustrating parasite development in the liver and red blood cells, as well as transmission between mosquito and human hosts.

Source: <https://image.slidesharecdn.com/jahnavi-200123122645/75/Malarial-parasite-morphology-and-lifecycle-mosquito-phase-15-2048.jpg>

Chronic Infection and Host Remodeling

Chronic parasitic infections often result in long-term alterations of host tissues and physiology. Persistent infection by helminths, for example, induces remodeling of the liver, intestines, and lymphatic system. Fibrosis in schistosomiasis is driven by prolonged inflammation and deposition of extracellular matrix proteins, leading to portal hypertension and hepatosplenic disease [91, 92]. Chronic *Trypanosoma cruzi* infection promotes cardiac remodeling, conduction abnormalities, and progressive cardiomyopathy through combined direct parasitic damage and sustained inflammatory responses. Parasite-induced metabolic and cellular remodeling also contributes to long-term host pathology [93–96]. *Plasmodium* infection alters erythrocyte deformability, oxidative stress balance, and nitric oxide bioavailability, while *Toxoplasma gondii* can manipulate neuronal signaling and immune surveillance, leading to latent infections with subtle but persistent consequences. Mapping these molecular changes provides critical insight into how chronic infection transitions into observable disease phenotypes [97].

Linking Molecular Fingerprints to Clinical Outcomes

The molecular fingerprints of parasites are intimately connected to clinical manifestations of disease. Proteins exported by parasites, host transcriptional changes, secreted metabolites, and immune response patterns all contribute to observable pathology. For example, PfEMP1 variants correlate with cerebral malaria severity, while GP63 expression in *Leishmania* correlates with tissue destruction and lesion progression. Helminth-secreted molecules can predict fibrosis severity and immune skewing in chronic infections [98–100]. High-throughput omics approaches have enabled the correlation of molecular signatures with disease outcomes. Proteomic and metabolomic profiling can identify host and parasite biomarkers predictive of severe disease, relapse, or treatment response. Transcriptomic analyses reveal immune activation patterns associated with specific clinical phenotypes, allowing researchers to link molecular fingerprints directly to tissue pathology and systemic illness [101–105].

Host Systems and Organ-Specific Pathology

Parasites exhibit tropism for particular organs, shaping both molecular fingerprints and disease manifestations. In malaria, sequestration of infected RBCs in the brain microvasculature leads to cerebral malaria, while liver-stage development contributes to hepatomegaly and metabolic alterations. In visceral leishmaniasis, infection of macrophages in the spleen and liver results in organ enlargement and cytopenias [106–110]. Helminth infections, such as *Schistosoma* species, target the liver and intestines, promoting fibrosis and portal hypertension. Each organ-specific infection leaves distinct molecular and cellular footprints, enabling the identification of biomarkers and diagnostic signatures.

Immunomodulation and Parasite Survival

Disease mechanisms are often shaped by parasite-induced immunomodulation. By manipulating host immune responses, parasites balance survival and pathology [111–114]. *Trypanosoma brucei* periodically changes its surface glycoproteins to evade antibodies, prolonging infection and allowing gradual organ damage. Helminths secrete immunomodulatory proteins that suppress inflammatory responses, promoting chronic infection while limiting overt tissue destruction [115–117]. This immunomodulatory fingerprint is detectable through cytokine profiling, transcriptional analysis, and metabolomics, linking host immune status to disease progression.

DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS

The concept of parasitic fingerprint has profound implications for both diagnosis and treatment of parasitic diseases. By identifying molecular, cellular, and immunological signatures left by parasites in host systems, researchers, and clinicians can develop sensitive diagnostic tools, targeted therapies, and personalized intervention strategies. The integration of multi-omics data with clinical phenotypes enhances precision medicine approaches, improving outcomes for patients suffering from parasitic infections [118–120].

Diagnostics Based on Parasitic Fingerprints

Traditional diagnostic methods, such as microscopy, serology, and culture, often lack sensitivity, specificity, or speed. The identification of molecular fingerprints provides a new paradigm for accurate and early detection [121–125]. Proteomic signatures, including parasite-derived proteins, such as PfEMP1 in malaria or GP63 in *Leishmania* infections, can be detected in blood or tissue samples, providing highly specific diagnostic markers. Genomic approaches, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), enable detection of parasite DNA or RNA even at low parasitemia levels [126, 127]. For instance, quantitative PCR targeting *Plasmodium* 18S rRNA genes can diagnose subclinical malaria infections, while NGS-based metagenomics can identify co-infections and novel parasites. Transcriptomic profiling of host responses can also indicate infection, as specific gene expression patterns are triggered by parasite-host interactions. Metabolomic and biochemical markers offer additional diagnostic opportunities. Changes in metabolites, such as hemozoin, polyamines, nitric oxide derivatives, and lipid profiles, can indicate parasite presence and disease stage [128–130]. Helminth infections, for example, alter amino acid and lipid metabolism, which can be detected in urine or serum as non-invasive biomarkers. Extracellular vesicles released by

parasites carry proteins, microRNAs, and lipids that provide a rich source of diagnostic information. Combining these multi-layered molecular signatures with computational models can enhance diagnostic accuracy and enable early detection before clinical symptoms manifest [131–133].

Targeted Therapies

Understanding the molecular fingerprints of parasites allows the development of highly specific therapies aimed at critical parasite survival pathways. For protozoan infections, drugs targeting exported proteins, enzymes, or metabolic pathways can inhibit parasite replication and reduce pathogenicity. Artemisinin derivatives for malaria, for example, target parasite hemoglobin metabolism and oxidative stress pathways, directly interfering with molecular processes reflected in the parasitic fingerprint. Helminth-targeted therapies exploit vulnerabilities in neuromuscular function, metabolism, or tegumental structures [134–136]. Drugs, such as praziquantel, induce calcium influx and tegumental disruption in schistosomes, while albendazole inhibits microtubule polymerization in nematodes. Understanding molecular footprints also enables drug repositioning and combination therapies that enhance efficacy while minimizing toxicity. Immunomodulatory therapies are particularly promising, as they can correct parasite-induced immune dysregulation without compromising protective responses. Cytokine modulators, immune checkpoint inhibitors, or small molecules targeting regulatory T cell pathways can counteract parasite-driven immunosuppression [137–140]. By leveraging molecular fingerprints, these interventions can be tailored to individual host responses, reducing disease severity and improving therapeutic outcomes.

Vaccine Development

Parasitic fingerprints also guide vaccine design by identifying immunogenic molecules critical for parasite survival or host-pathogen interactions. Surface proteins, secreted enzymes, and extracellular vesicle components serve as potential vaccine targets [141, 142]. For example, PfEMP1, and circumsporozoite protein (CSP) in *Plasmodium* are being investigated as vaccine candidates, as they are central to parasite invasion and immune evasion. *Leishmania* GP63, a protease involved in macrophage manipulation, represents another promising target. Vaccines designed to elicit strong humoral and cellular immune responses against these molecules can prevent infection or reduce disease severity [143–145]. Multi-epitope vaccines and recombinant protein formulations benefit from knowledge of molecular fingerprints, as they enable the selection of conserved, immunodominant antigens while avoiding cross-reactivity.

Personalized Medicine Approaches

The integration of parasitic fingerprints with host genetic and immunological data facilitates personalized medicine strategies. Host-specific molecular signatures, including transcriptomic, proteomic, and metabolomic profiles, can predict susceptibility, disease severity, and response to therapy [146–150]. For example, host cytokine profiles can indicate the risk of severe malaria or visceral leishmaniasis, guiding prophylactic or therapeutic interventions. High-resolution omics analyses allow stratification of patients based on molecular risk factors, enabling individualized treatment regimens. Patients with high-risk molecular signatures may benefit from early aggressive therapy, while low-risk individuals may require supportive care and monitoring. This approach maximizes efficacy, minimizes adverse effects, and optimizes resource allocation in endemic regions.

Challenges and Future Directions in Diagnostics and Therapy

Despite the promise of molecular fingerprints, several challenges remain. The heterogeneity of parasite strains, co-infections, and host genetic diversity complicates the identification of universal biomarkers. Additionally, high-throughput omics technologies can be resource-intensive and require sophisticated computational analysis, limiting accessibility in low-resource settings where parasitic diseases are most prevalent [151, 152]. Future research should focus on standardizing molecular fingerprint assays, integrating multi-omics data, and developing portable diagnostic platforms. Point-of-care devices leveraging proteomic or metabolomic signatures could enable rapid, accurate detection in endemic areas. On the therapeutic side, combining molecular fingerprint information with drug

discovery pipelines, immunotherapy, and vaccine development will enhance precision and efficacy [153–155].

CASE STUDIES OF PARASITIC FINGERPRINTS

Examining specific parasitic infections illustrates how molecular fingerprints link infection to host illness. Here, malaria, leishmaniasis, trypanosomiasis, and helminth infections are reviewed as representative cases, highlighting how parasite-induced molecular and immunological signatures correspond to disease pathogenesis and clinical outcomes.

Malaria (*Plasmodium* spp.)

Malaria, caused primarily by *Plasmodium falciparum* and *Plasmodium vivax*, remains a major global health challenge. The parasitic fingerprint in malaria is characterized by both parasite-derived molecules and host responses [156, 157]. Parasite proteins are exported to erythrocytes, such as PfEMP1, RIFINs, and STEVORs, alter red blood cell deformability, adhesion properties, and immune recognition. These changes contribute to microvascular obstruction, anemia, and cerebral malaria. Host molecular responses include upregulation of pro-inflammatory cytokines (TNF- α , IFN- γ , IL-6) and oxidative stress markers, which contribute to fever, tissue damage, and systemic inflammation. Metabolomic studies reveal depletion of glucose and amino acids in plasma, alongside accumulation of parasite-specific metabolites like hemozoin. The combined profiling of parasite proteins, host cytokines, and metabolites constitutes a molecular fingerprint that correlates with disease severity and informs prognosis.

Leishmaniasis

Leishmaniasis, caused by *Leishmania* species, demonstrates how intracellular parasites manipulate host macrophages to survive. The GP63 metalloprotease and lipophosphoglycan (LPG) are secreted by the parasite modulate host signaling pathways, suppressing pro-inflammatory cytokine production and inhibiting antigen presentation. This molecular interference allows the parasite to persist in tissues such as skin, spleen, and liver. Host transcriptomic and proteomic analyses reveal altered expression of immune regulatory genes, including IL-10 and TGF- β , which promote immune tolerance and chronic infection. Metabolomic profiling shows changes in amino acid and lipid metabolism, reflecting both parasite consumption and host immune adaptation [158–160]. These molecular signatures provide diagnostic markers for visceral versus cutaneous forms of the disease and predict clinical outcomes, including organ enlargement and cytopenias.

Trypanosomiasis

Trypanosomiasis, caused by *Trypanosoma brucei* (African sleeping sickness) and *Trypanosoma cruzi* (Chagas disease), illustrates the role of antigenic variation and host immune modulation in disease progression. *T. brucei* periodically changes its variant surface glycoproteins (VSGs), evading antibody detection and sustaining chronic infection. These VSG switching events constitute a dynamic molecular fingerprint associated with parasitemia waves and disease severity. In *T. cruzi* infection, the parasite invades cardiac and smooth muscle cells, causing direct cytolysis and chronic inflammation. Host transcriptomic and proteomic profiling shows upregulation of inflammatory cytokines and oxidative stress pathways, while metabolomic analysis indicates mitochondrial dysfunction and altered energy metabolism in cardiac tissues [161, 162]. The molecular fingerprints of trypanosomiasis thus reflect both parasite survival strategies and host tissue remodeling, linking infection to cardiomyopathy, neurological symptoms, and systemic illness.

Helminth Infections

Helminths, such as *Schistosoma*, *Ascaris*, and *Fasciola* species, cause chronic infections that reshape host tissues and immune responses. Parasite excretory–secretory products, including proteases, glycoproteins, and immunomodulatory molecules, induce fibrosis, angiogenesis, and Th2-skewed immune responses. These molecules form identifiable molecular fingerprints in host serum and tissue, reflecting both parasite activity and host adaptation. Host molecular signatures include elevated levels

of IL-4, IL-5, and IL-13 cytokines, eosinophilia, and changes in collagen and extracellular matrix components in affected tissues. Metabolomic studies reveal altered lipid metabolism, oxidative stress markers, and vitamin deficiencies [143]. Chronic helminth infections also induce epigenetic modifications, including DNA methylation changes that affect immune gene expression. Together, these molecular and cellular fingerprints explain the clinical manifestations of organomegaly, anaemia, growth retardation, and fibrosis.

Integration of Case Studies

Across these case studies, a common theme emerges: the parasitic fingerprint integrates parasite-derived molecules, host immune responses, metabolic alterations, and tissue-specific changes to link infection with disease outcomes. In malaria, fingerprints correlate with acute severity and organ dysfunction; in leishmaniasis, they predict chronicity and organ involvement; in trypanosomiasis, they reflect cycles of immune evasion and tissue damage; and in helminth infections, they explain long-term pathology and immune modulation. High-throughput multi-omics approaches—combining proteomics, transcriptomics, metabolomics, and epigenomics—allow researchers to map these fingerprints comprehensively. Integrating molecular data with clinical phenotypes enhances the ability to predict disease progression, identify early biomarkers, and design targeted interventions [133–135]. The case studies illustrate the practical value of the parasitic fingerprint concept for understanding disease mechanisms, improving diagnostics, and guiding therapeutics.

FUTURE DIRECTIONS AND RESEARCH GAPS

The concept of the parasitic fingerprint offers a promising framework for understanding the progression from infection to host illness [1, 2]. Despite advances in molecular biology, omics technologies, and immunology, several critical knowledge gaps remain. Addressing these gaps will improve disease prediction, diagnostic accuracy, therapeutic strategies, and the overall understanding of host–parasite interactions.

High-Resolution Molecular Mapping

While current studies have identified numerous parasite-derived molecules and host response markers, comprehensive, high-resolution mapping of the parasitic fingerprint remains incomplete. Multi-omics approaches integrating genomics, transcriptomics, proteomics, metabolomics, and epigenomics are essential to capture the full complexity of host–parasite interactions. For instance, single-cell RNA sequencing can reveal cell-type-specific host responses, while spatial proteomics can identify tissue-specific parasite protein localization [55–57]. Future research should focus on constructing detailed molecular atlases of infection stages, tissue tropism, and host immune modulation. High-resolution mapping will enable researchers to pinpoint critical nodes in host–parasite interactions that drive pathology, guiding the development of targeted diagnostics and therapies.

Integration with Systems Biology and Computational Modelling

Systems biology approaches offer opportunities to integrate large-scale molecular data with host physiology, clinical outcomes, and epidemiological trends. Computational models can simulate host–parasite interactions, predict disease progression, and identify key molecular drivers of pathology. Machine learning algorithms can analyze multi-omics datasets to discover novel biomarkers, classify infection severity, and predict therapeutic responses. Integrating parasitic fingerprints with systems biology will allow a more holistic understanding of infection dynamics, bridging molecular signatures with clinical phenotypes [11, 12]. Predictive models could facilitate personalized medicine approaches, enabling interventions tailored to individual molecular and immunological profiles.

Translational Opportunities in Diagnostics

The molecular signatures identified in parasitic fingerprints hold great promise for translational applications. Development of rapid, point-of-care diagnostics based on proteomic, metabolomic, or transcriptomic markers could revolutionize disease detection, particularly in resource-limited endemic regions. Portable platforms, such as microfluidic devices, biosensors, and lateral-flow assays, could

detect parasite-specific proteins, nucleic acids, or metabolites with high sensitivity and specificity. Further research is needed to validate these biomarkers across diverse parasite strains, host populations, and disease stages. Standardizing molecular fingerprint assays and ensuring reproducibility will be critical for clinical implementation. Integration of molecular diagnostics with traditional methods could enhance accuracy, speed, and patient outcomes.

Therapeutic and Vaccine Development

Understanding the molecular and immunological fingerprints of parasites informs targeted therapeutic strategies. Future research should explore drugs that disrupt parasite-specific pathways, secreted factors, or immune evasion mechanisms identified in the fingerprint. Combination therapies guided by molecular signatures may enhance efficacy and reduce resistance development. Vaccine development can also benefit from fingerprint-guided approaches. Identifying conserved, immunogenic parasite molecules that contribute to survival or pathogenesis enables rational vaccine design. Multi-epitope, recombinant, or nanoparticle-based vaccines targeting critical fingerprint molecules could induce protective immunity while minimizing off-target effects. Additionally, immunomodulatory therapies that restore host immune balance disrupted by parasite fingerprints could improve outcomes in chronic infections.

Host-Parasite Co-Evolution and Molecular Diversity

Parasites exhibit remarkable genetic and phenotypic diversity, resulting in variation in molecular fingerprints across strains, species, and geographic regions. Understanding how host genetics and immune status interact with parasite variability is crucial for interpreting molecular signatures and predicting disease outcomes. Future studies should investigate co-evolutionary dynamics, including how host immune pressures shape parasite molecular strategies and vice versa. Comparative studies across populations and species can identify conserved molecular fingerprints, informing universal diagnostics and therapeutic targets.

Knowledge Gaps and Research Challenges

Despite advances, several challenges persist:

- *Heterogeneity of Fingerprints*: Molecular signatures vary by parasite species, strain, infection stage, and host genetics. Identifying robust, reproducible markers remains a challenge.
- *Limited Access in Endemic Regions*: High-throughput omics technologies often require resources unavailable in areas most affected by parasitic diseases. Developing cost-effective, field-adapted assays is critical.
- *Integration of Multi-Layered Data*: Combining proteomic, transcriptomic, metabolomic, and clinical data is computationally complex. Standardized frameworks for data integration are needed.
- *Longitudinal Studies*: Understanding how fingerprints evolve over time during acute and chronic infections require longitudinal sampling and analysis, which is currently limited.

Addressing these challenges will improve the reliability, applicability, and translational impact of parasitic fingerprint research.

Emerging Technologies and Future Directions

Several emerging technologies offer new avenues for fingerprint research:

- *Single-Cell Multi-Omics*: Captures host and parasite signatures at the cellular level, revealing heterogeneity in infection and immune responses.
- *Spatial Transcriptomics and Proteomics*: Maps molecular fingerprints within tissue architecture, linking local parasite activity to organ-specific pathology.
- *Artificial Intelligence and Machine Learning*: Facilitates pattern recognition, biomarker discovery, and predictive modelling of disease outcomes based on molecular fingerprints.
- *CRISPR-Cas9 and Gene Editing*: Enables functional validation of fingerprint molecules and exploration of parasite survival strategies.

- *Point-of-Care Biosensors*: Translates fingerprint-based diagnostics to field-deployable, real-time detection platforms.

By leveraging these technologies, future research can enhance our understanding of parasitic fingerprints, improve early detection, optimize therapeutic strategies, and ultimately reduce the global burden of parasitic diseases.

CONCLUSION

Parasitic infections remain a significant global health challenge, causing extensive morbidity and mortality across diverse populations. Understanding the pathogenesis of these diseases requires a comprehensive view of the interactions between parasites and their hosts. The concept of the “parasitic fingerprint” provides such a framework, linking the molecular, cellular, and immunological signatures left by parasites to the clinical manifestations of disease. By tracing these fingerprints, researchers can connect the initial infection to tissue-specific pathology, immune dysregulation, and long-term illness. Molecular fingerprints encompass parasite-derived proteins, secreted factors, nucleic acids, metabolites, and extracellular vesicles, alongside host responses including gene expression changes, cytokine profiles, and metabolic adaptations. Multi-omics approaches integrating proteomics, genomics, transcriptomics, metabolomics, and epigenomics have greatly enhanced the ability to characterize these signatures at high resolution. Such analyses reveal the strategies parasites employ to invade, survive, and manipulate host systems, while also identifying host pathways critical for immunity and disease progression. The clinical relevance of parasitic fingerprints is substantial. They provide precise biomarkers for early and accurate diagnosis, enable stratification of disease severity, and inform prognosis. Furthermore, fingerprint-guided research supports the development of targeted therapeutics, vaccines, and immunomodulatory interventions. Personalized medicine approaches, informed by host and parasite molecular signatures, promise optimized treatment strategies and improved patient outcomes, particularly in regions heavily burdened by parasitic diseases. Despite these advances, challenges remain. Parasite diversity, host heterogeneity, resource limitations, and the complexity of multi-omics integration hinder the translation of molecular fingerprints into practical applications. Addressing these gaps through high-resolution mapping, longitudinal studies, and emerging technologies, such as single-cell multi-omics, spatial transcriptomics, and artificial intelligence, will enhance the understanding of host–parasite interactions and accelerate translational research.

Declarations

Ethics and Consent to Participate

Not Applicable.

Consent for Publication

Not Applicable.

Availability of Data and Materials

Not Applicable.

Competing Interests

The authors declare no competing interests.

Funding

There was no funding for this review article.

Author's Information

- *Shubham Sah*: School of Biology, Indian Institute of Science Education and Research (IISER), Thiruvananthapuram, Kerala, India.
- *Deepa Kumari*: Department of Biochemistry, Central University of Haryana (CUH), Mahendergarh, Haryana, India.

Authors' Contributions

Shubham Sah (SS) and Deepa Kumari (DK) contributed to the conception, drafting, literature review, data interpretation, and critical revision of the manuscript. Both authors read and approved the final version of the manuscript.

Acknowledgments

Sincere gratitude is extended to the Indian Institute of Science Education and Research, Thiruvananthapuram, and the Central University of Haryana, Mahendergarh, for their continuous academic support. Special thanks are extended by Shubham Sah and Deepa Kumari to their mentors, colleagues, and peers for creating an encouraging environment that inspired this review and for the constructive discussions that shaped its final form.

REFERENCES

1. World Health Organization. Soil-transmitted helminth infections [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Feb 5]. Available from: <https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections>
2. Hotez PJ, et al. The global burden of parasitic diseases. *N Engl J Med*. 2018;379:2380–2389. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMra1803471>
3. Petri WA Jr, Haque R. Host–parasite interactions in protozoan infections. *Annu Rev Pathol*. 2019;14:353–379. Available from: <https://www.annualreviews.org/doi/10.1146/annurev-pathmechdis-012418-012754>
4. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: Cellular and molecular mechanisms. *Nat Rev Immunol*. 2018;18:270–283. Available from: <https://www.nature.com/articles/nri.2018.10>
5. Allen JE, Maizels RM. Diversity and dialogue in immunity to helminths. *Nat Rev Immunol*. 2011;11:375–388. Available from: <https://www.nature.com/articles/nri2991>
6. Torgerson PR, Macpherson CNL. The socioeconomic burden of parasitic zoonoses: Global trends. *Vet Parasitol*. 2011;182:79–95. Available from: <https://www.sciencedirect.com/science/article/pii/S0304401711002571>
7. Blackwell JM, Searle S. Host–pathogen interactions and immune evasion strategies in protozoan infections. *Parasite Immunol*. 2017;39:e12421. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/pim.12421>
8. Dobson A, et al. Epidemiology of parasitic infections and molecular signatures of host response. *Parasit Vectors*. 2020;13:450. Available from: <https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-020-04325-8>
9. Loke P, Allen JE. The parasitic worm host–parasite interface. *Nat Rev Immunol*. 2004;4:1–12. Available from: <https://www.nature.com/articles/nri1316>
10. Cornick S, Nevins JR. Parasite–host molecular interactions: Insights from multi-omics studies. *PLoS Pathog*. 2018;14:e1007177. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1007177>
11. Zhou Y, et al. Integration of multi-omics approaches to understand parasitic infections. *Trends Parasitol*. 2020;36:632–644. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492220300927>
12. Aksoy S, et al. Host–parasite molecular fingerprinting: Implications for diagnostics and therapeutics. *Front Cell Infect Microbiol*. 2021;11:703412. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2021.703412/full>
13. Walker MJ, et al. Immune modulation by parasites: Molecular mechanisms and clinical implications. *Clin Exp Immunol*. 2019;196:315–330. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642401/>
14. Figueiredo C, et al. Proteomic insights into host–parasite interactions. *Mol Biochem Parasitol*. 2022;248:111525. Available from: <https://www.sciencedirect.com/science/article/pii/S016685122000687>

15. Antony B, et al. Parasitic infection-induced transcriptomic signatures in humans. *Nat Commun.* 2021;12:1547. Available from: <https://www.nature.com/articles/s41467-021-21842-2>
16. Maizels RM, McSorley HJ. Regulation of the host immune system by helminth parasites. *J Allergy Clin Immunol.* 2016;138:666–675. Available from: [https://www.jacionline.org/article/S0091-6749\(16\)30512-6/fulltext](https://www.jacionline.org/article/S0091-6749(16)30512-6/fulltext)
17. Casadevall A, Pirofski LA. Host–pathogen interactions: The path to a molecular understanding. *Cell.* 2000;102:239–242. Available from: <https://www.sciencedirect.com/science/article/pii/S0092867400007365>
18. Desowitz RS. *The malaria capers: More tales of parasites and people.* New York: W. W. Norton & Company; 1991. Available from: <https://books.wwnorton.com/books/the-malaria-capers>
19. Maizels RM. Parasitic fingerprints: Molecular signatures and the immunological footprint of helminth infections. *Curr Opin Immunol.* 2020;66:1–8. Available from: <https://www.sciencedirect.com/science/article/pii/S0952791520300759>
20. World Health Organization. Parasitic diseases overview [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Feb 5]. Available from: <https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections>
21. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: Cellular and molecular mechanisms. *Nat Rev Immunol.* 2003;3:733–744. Available from: <https://www.nature.com/articles/nri1183>
22. Blackwell JM, Searle S. Host–pathogen interactions in protozoan infections. *Parasite Immunol.* 2017;39:e12421. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/pim.12421>
23. Loke P, Allen JE. The parasitic worm host–parasite interface. *Nat Rev Immunol.* 2004;4:1–12. Available from: <https://www.nature.com/articles/nri1316>
24. Desowitz RS. *The malaria capers: More tales of parasites and people.* New York: W. W. Norton & Company; 1991. Available from: <https://books.wwnorton.com/books/the-malaria-capers>
25. Petri WA Jr, Haque R. Host–parasite interactions in protozoan infections. *Annu Rev Pathol.* 2019;14:353–379. Available from: <https://www.annualreviews.org/doi/10.1146/annurev-pathmechdis-012418-012754>
26. Allen JE, Maizels RM. Diversity and dialogue in immunity to helminths. *Nat Rev Immunol.* 2011;11:375–388. Available from: <https://www.nature.com/articles/nri2991>
27. Cornick S, Nevins JR. Parasite–host molecular interactions: Insights from multi-omics studies. *PLoS Pathog.* 2018;14:e1007177. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1007177>
28. Walker MJ, et al. Immune modulation by parasites: Molecular mechanisms and clinical implications. *Clin Exp Immunol.* 2019;196:315–330. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642401/>
29. Antony B, et al. Parasitic infection-induced transcriptomic signatures in humans. *Nat Commun.* 2021;12:1547. Available from: <https://www.nature.com/articles/s41467-021-21842-2>
30. Berriman M, et al. The genome of the blood fluke *Schistosoma mansoni*. *Nature.* 2009;460:352–358. Available from: <https://www.nature.com/articles/nature08160>
31. Zhou Y, et al. Integration of multi-omics approaches to understand parasitic infections. *Trends Parasitol.* 2020;36:632–644. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492220300927>
32. Aksoy S, et al. Host–parasite molecular fingerprinting: Implications for diagnostics and therapeutics. *Front Cell Infect Microbiol.* 2021;11:703412. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2021.703412/full>
33. Figueiredo C, et al. Proteomic insights into host–parasite interactions. *Mol Biochem Parasitol.* 2022;248:111525. Available from: <https://www.sciencedirect.com/science/article/pii/S0166685122000687>
34. Casadevall A, Pirofski LA. Host–pathogen interactions: The path to a molecular understanding. *Cell.* 2000;102:239–242. Available from: <https://www.sciencedirect.com/science/article/pii/S0092867400007365>

35. Hotez PJ, et al. The global burden of parasitic diseases. *N Engl J Med*. 2018;379:2380–2389. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMra1803471>
36. Maizels RM, McSorley HJ. Regulation of the host immune system by helminth parasites. *J Allergy Clin Immunol*. 2016;138:666–675. Available from: [https://www.jacionline.org/article/S0091-6749\(16\)30512-6/fulltext](https://www.jacionline.org/article/S0091-6749(16)30512-6/fulltext)
37. Blackwell JM. Host immune responses to *Leishmania* and tissue tropism. *Parasite Immunol*. 2010;32:199–210. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-3024.2010.01205.x>
38. Boothroyd JC, Dubey JP. Toxoplasmosis: From animals to humans. *Int J Parasitol*. 2008;38:1257–1278. Available from: <https://www.sciencedirect.com/science/article/pii/S0020751908001047>
39. Maizels RM. Parasitic fingerprints: Molecular signatures and the immunological footprint of helminth infections. *Curr Opin Immunol*. 2020;66:1–8. Available from: <https://www.sciencedirect.com/science/article/pii/S0952791520300759>
40. Olliaro P, Wells TNC. Parasitic diseases: Molecular and clinical insights. *PLoS Negl Trop Dis*. 2019;13(10):e0007625. Available from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007625>
41. Smith JD, et al. Switching of PfEMP1 in *Plasmodium falciparum* and immune evasion. *Science*. 2000;287(5459):1281–1284. Available from: <https://www.science.org/doi/10.1126/science.287.5459.1281>
42. Choi J, et al. Proteomic profiling of *Leishmania*-infected macrophages. *Mol Cell Proteomics*. 2019;18(2):242–256. Available from: <https://www.mcponline.org/content/18/2/242>
43. Florens L, et al. Proteomic analysis of *Plasmodium falciparum*. *Nature*. 2002;419:520–526. Available from: <https://www.nature.com/articles/nature01097>
44. Debrabant A, et al. *Leishmania* GP63-mediated modulation of host cell signaling. *Infect Immun*. 2004;72(6):3462–3470. Available from: <https://journals.asm.org/doi/10.1128/IAI.72.6.3462-3470.2004>
45. Sahoo N, et al. Host transcriptomic changes in malaria infection. *Front Immunol*. 2020;11:583. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2020.00583/full>
46. Hunter CA, Sibley LD. Modulation of host gene expression by *Toxoplasma gondii*. *Trends Parasitol*. 2012;28(10):450–456. Available from: <https://www.sciencedirect.com/science/article/pii/S147149221200104X>
47. Papatheodorou P, et al. Epigenetic modulation during parasitic infections. *Nat Rev Microbiol*. 2020;18:347–360. Available from: <https://www.nature.com/articles/s41579-020-0354-3>
48. O'Neill LA, et al. Metabolomic profiling in infectious diseases. *Cell Host Microbe*. 2016;19(5):640–652. Available from: <https://www.sciencedirect.com/science/article/pii/S1931312816301924>
49. Saggu G, et al. Metabolic alterations in helminth-infected hosts. *Front Cell Infect Microbiol*. 2021;11:676891. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2021.676891/full>
50. Mantel PY, et al. *Plasmodium falciparum* microvesicles and host immune modulation. *PLoS Pathog*. 2013;9(10):e1003720. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003720>
51. Silverman JM, et al. Exosomes in *Leishmania* infection. *PLoS Pathog*. 2010;6(12):e1001209. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1001209>
52. Rojas-Peña M, et al. Extracellular vesicles in parasitic disease pathogenesis. *Trends Parasitol*. 2018;34(7):622–636. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492218301006>
53. Siqueira-Neto JL, et al. Integrative omics approaches in parasitology. *Trends Parasitol*. 2018;34(10):814–827. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492218301532>
54. Tonkin-Hill G, et al. Transcriptomic mapping of *Plasmodium falciparum* infections. *PLoS Genet*. 2018;14(5):e1007302. Available from: <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1007302>

55. Cross GA. Antigenic variation in trypanosomes. *Annu Rev Microbiol.* 1996;50:437–462. Available from: <https://www.annualreviews.org/doi/10.1146/annurev.micro.50.1.437>
56. Silvie O, et al. Host–parasite interactions during Plasmodium liver stage. *Curr Opin Microbiol.* 2008;11(4):362–369. Available from: <https://www.sciencedirect.com/science/article/pii/S1369527408000660>
57. Roy S, et al. Multi-omics in parasitic infections: Integration of molecular data. *Front Cell Infect Microbiol.* 2018;8:284. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2018.00284/full>
58. Cobbold SA, et al. Proteomic and metabolomic signatures of malaria pathogenesis. *Mol Biochem Parasitol.* 2016;208:65–74. Available from: <https://www.sciencedirect.com/science/article/pii/S0166685116300640>
59. Maizels RM. Parasitic fingerprints: Molecular and immunological signatures of infection. *Curr Opin Immunol.* 2020;66:1–8. Available from: <https://www.sciencedirect.com/science/article/pii/S0952791520300759>
60. White NJ. Malaria parasite biology, pathogenesis and disease mechanisms. *Nat Rev Microbiol.* 2018;16:93–105. Available from: <https://www.nature.com/articles/nrmicro.2017.161>
61. Cowman AF, et al. Plasmodium falciparum invasion and erythrocyte remodeling. *Nat Rev Microbiol.* 2017;15(1):45–58. Available from: <https://www.nature.com/articles/nrmicro.2016.161>
62. Menezes CH, et al. Trypanosoma cruzi-induced cardiomyopathy: Molecular insights. *Front Immunol.* 2019;10:2455. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.02455/full>
63. McManus DP, et al. Schistosomiasis and host tissue pathology. *Nat Rev Dis Primers.* 2018;4:13. Available from: <https://www.nature.com/articles/s41572-018-0004-2>
64. Hotez PJ, et al. Helminth infections and chronic host remodeling. *PLoS Negl Trop Dis.* 2020;14(1):e0008009. Available from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008009>
65. Idro R, et al. Cerebral malaria pathogenesis: Immunopathology and vascular effects. *Clin Microbiol Rev.* 2010;23(1):129–142. Available from: <https://journals.asm.org/doi/10.1128/CMR.00004-09>
66. Olivier M, et al. Leishmania-induced immunopathology. *Trends Parasitol.* 2005;21(7):332–338. Available from: <https://www.sciencedirect.com/science/article/pii/S147149220500118X>
67. Gazzinelli RT, et al. Host immune responses and pathology in parasitic infections. *Nat Rev Immunol.* 2014;14(4):219–231. Available from: <https://www.nature.com/articles/nri3630>
68. Fallon PG, Dunne DW. Helminth-induced Th2 responses and tissue fibrosis. *Curr Opin Immunol.* 2015;36:63–70. Available from: <https://www.sciencedirect.com/science/article/pii/S0952791515000657>
69. Schofield L, Grau GE. Immunopathogenesis of malaria. *Curr Mol Med.* 2005;5(1):77–88. Available from: <https://www.eurekaselect.com/75061/article>
70. Rossi M, Fasel N. Leishmania-host interactions: Tissue pathology and immune modulation. *Parasitology.* 2018;145(7):965–975. Available from: <https://www.cambridge.org/core/journals/parasitology/article/abs/leishmaniahost-interactions-tissue-pathology-and-immune-modulation/>
71. Andrade LO, Andrews NW. Trypanosoma cruzi invasion and host cell remodeling. *Annu Rev Microbiol.* 2005;59:367–401. Available from: <https://www.annualreviews.org/doi/10.1146/annurev.micro.59.030804.121218>
72. Fabre S, et al. Chronic parasitic infection and host organ remodeling. *Trends Parasitol.* 2012;28(10):420–426. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492212001051>
73. Cohen JM, et al. Host–parasite interactions and severe malaria pathology. *PLoS Pathog.* 2015;11(2):e1004579. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1004579>
74. Pearce EJ, MacDonald AS. The immunology of schistosomiasis. *Nat Rev Immunol.* 2002;2(7):499–511. Available from: <https://www.nature.com/articles/nri843>
75. Shapira S, et al. Plasmodium-induced endothelial activation and immunopathology. *Infect Immun.* 2008;76(12):5629–5638. Available from: <https://journals.asm.org/doi/10.1128/IAI.00815-08>

76. Wilson MS, Maizels RM. Helminth immunomodulation and host survival. *Parasite Immunol.* 2004;26(6–7):311–319. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.0141-9838.2004.00711.x>
77. Kaye P, et al. Leishmania immunopathology: Linking parasite to disease outcome. *Curr Opin Immunol.* 2004;16(4):450–456. Available from: <https://www.sciencedirect.com/science/article/pii/S0952791504000870>
78. Rassi A Jr, et al. Chagas disease pathophysiology and clinical outcomes. *Circulation.* 2010;121(14):1693–1704. Available from: <https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.109.881887>
79. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: Implications for chronic infection. *Nat Rev Immunol.* 2003;3(9):733–744. Available from: <https://www.nature.com/articles/nri1183>
80. World Health Organization. World malaria report 2022. Geneva: World Health Organization; 2022. Available from: <https://www.who.int/publications/i/item/9789240064898>
81. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and disease mechanisms. *Cell.* 2016;167(3):610–624. Available from: [https://www.cell.com/cell/fulltext/S0092-8674\(16\)30130-9](https://www.cell.com/cell/fulltext/S0092-8674(16)30130-9)
82. White NJ. Malaria parasite biology, pathogenesis, and therapeutic targets. *Nat Rev Microbiol.* 2018;16(2):93–105. Available from: <https://www.nature.com/articles/nrmicro.2017.161>
83. Dockrell HM, et al. Immune-based diagnostics for parasitic diseases. *Expert Rev Mol Diagn.* 2012;12(7):705–719. Available from: <https://www.tandfonline.com/doi/full/10.1586/erm.12.61>
84. Mwangi W, et al. Molecular biomarkers for malaria diagnosis and prognosis. *Parasite Immunol.* 2016;38(8):501–514. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/pim.12338>
85. Lu G, et al. Multi-omics for host–parasite interaction profiling. *Trends Parasitol.* 2018;34(5):412–425. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492217301630>
86. Fairhurst RM, Wellems TE. Plasmodium falciparum antigens as therapeutic and vaccine targets. *Clin Microbiol Rev.* 2010;23(3):508–541. Available from: <https://journals.asm.org/doi/full/10.1128/CMR.00048-09>
87. Camargo M, et al. Next-generation sequencing and metagenomics in parasitic diagnostics. *Curr Opin Infect Dis.* 2020;33(5):413–423. Available from: https://journals.lww.com/co-infectiousdiseases/fulltext/2020/10000/next_generation_sequencing_and_metagenomics_in.9.aspx
88. Doolan DL, et al. Vaccines against malaria: Multi-epitope approaches. *Nat Rev Microbiol.* 2009;7(10):741–754. Available from: <https://www.nature.com/articles/nrmicro2204>
89. Olivier M, Gregory DJ, Forget G. Leishmania GP63 as a therapeutic target and diagnostic marker. *Trends Parasitol.* 2005;21(11):500–508. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492205001506>
90. Khosravi A, Mazumder R. Metabolomic signatures in parasitic infections for diagnostics. *Front Cell Infect Microbiol.* 2019;9:431. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2019.00431/full>
91. Tuteja R. Malaria drug targets: Parasite-specific pathways and molecular footprints. *Curr Sci.* 2007;93(6):753–761. Available from: https://www.currentscience.ac.in/Downloads/article_id_093_06_0753_0761_0.pdf
92. Hotez PJ, et al. Helminth diagnostics and immunomodulatory therapies. *PLoS Negl Trop Dis.* 2020;14(1):e0008009. Available from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008009>
93. Moorthy V, Ballou R. Malaria vaccine development: Lessons from molecular targets. *Nat Rev Microbiol.* 2009;7(1):30–36. Available from: <https://www.nature.com/articles/nrmicro2060>
94. Strickland C, et al. Extracellular vesicles as biomarkers for parasitic infections. *J Extracell Vesicles.* 2019;8(1):1596715. Available from: <https://www.tandfonline.com/doi/full/10.1080/20013078.2019.1596715>
95. Trager W, Jensen JB. Parasite survival pathways as therapeutic targets. *Trends Parasitol.* 2005;21(2):83–87. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492204010293>

96. Doolan DL, Hoffman SL. Plasmodium and Leishmania vaccines: Molecular fingerprint-guided approaches. *Nat Rev Microbiol.* 2000;1:224–233. Available from: <https://www.nature.com/articles/nrmicro773>
97. Singh B, Daneshvar C. Multi-omics and personalized medicine in parasitic diseases. *Clin Microbiol Rev.* 2013;26(1):50–69. Available from: <https://journals.asm.org/doi/full/10.1128/CMR.00033-12>
98. Freitas-Junior LH, et al. PfEMP1 molecular diversity and therapeutic implications. *Nat Rev Microbiol.* 2005;3(8):645–655. Available from: <https://www.nature.com/articles/nrmicro1211>
99. Yazdanbakhsh M, et al. Host immune response profiling and precision therapy for helminth infections. *Nat Rev Immunol.* 2002;2(8):589–598. Available from: <https://www.nature.com/articles/nri843>
100. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and disease mechanisms. *Cell.* 2016;167(3):610–624. Available from: [https://www.cell.com/cell/fulltext/S0092-8674\(16\)30130-9](https://www.cell.com/cell/fulltext/S0092-8674(16)30130-9)
101. White NJ. Malaria parasite biology, pathogenesis, and therapeutic targets. *Nat Rev Microbiol.* 2018;16(2):93–105. Available from: <https://www.nature.com/articles/nrmicro.2017.161>
102. Miller LH, et al. Plasmodium falciparum erythrocyte membrane protein 1 and malaria pathogenesis. *Nat Rev Microbiol.* 2003;1(2):124–135. Available from: <https://www.nature.com/articles/nrmicro739>
103. Miller KR, et al. Metabolomic profiling of Plasmodium infection. *Front Cell Infect Microbiol.* 2020;10:548. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2020.00548/full>
104. Olivier M, Gregory DJ, Forget G. Leishmania GP63 as a therapeutic target and diagnostic marker. *Trends Parasitol.* 2005;21(11):500–508. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492205001506>
105. Kaye P, Scott P. Leishmaniasis: Complexity at the host–pathogen interface. *Nat Rev Microbiol.* 2011;9(8):604–615. Available from: <https://www.nature.com/articles/nrmicro2608>
106. Handman E. Leishmania infection and macrophage manipulation. *Parasitol Today.* 2001;17(11):474–477. Available from: <https://www.sciencedirect.com/science/article/pii/S0169475801025697>
107. Kennedy PGE, Rodgers J. Clinical and molecular aspects of human African trypanosomiasis. *Adv Parasitol.* 2019;104:123–170. Available from: <https://www.sciencedirect.com/science/article/pii/S0065308X18300638>
108. Jackson AP, et al. Variant surface glycoprotein switching in Trypanosoma brucei. *PLoS Pathog.* 2013;9(8):e1003272. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003272>
109. Rassi A Jr, et al. Chagas disease: Pathogenesis and molecular fingerprints. *Lancet.* 2010;375(9723):1388–1402. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)60061-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60061-X/fulltext)
110. Hotez PJ, et al. Helminth infections and host immune modulation. *PLoS Negl Trop Dis.* 2020;14(1):e0008009. Available from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008009>
111. McSorley HJ, Maizels RM. Helminth immunomodulation and chronic infection. *Nat Rev Immunol.* 2012;12(3):203–216. Available from: <https://www.nature.com/articles/nri3178>
112. Pearce EJ, MacDonald AS. The immunobiology of helminth infections. *Nat Rev Immunol.* 2002;2(5):367–379. Available from: <https://www.nature.com/articles/nri803>
113. Ferreira RC, et al. Multi-omics of Plasmodium-host interactions. *Front Cell Infect Microbiol.* 2021;11:684738. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2021.684738/full>
114. Leal LH, et al. Leishmania-host molecular interactions: Transcriptomic and proteomic insights. *Front Cell Infect Microbiol.* 2020;10:572. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2020.00572/full>

115. Gluenz E, et al. Trypanosoma brucei antigenic variation and molecular fingerprints. *Mol Microbiol.* 2011;80(5):1148–1163. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2958.2011.07642.x>
116. Oliveira F, et al. Extracellular vesicles in helminth-host communication. *Front Immunol.* 2019;10:2547. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.02547/full>
117. Mantel PY, Marti M. Extracellular vesicles and malaria pathogenesis. *Cell Microbiol.* 2014;16(5):745–754. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/cmi.12258>
118. Andrade F, et al. Host–parasite molecular interplay in Chagas cardiomyopathy. *Front Immunol.* 2016;7:363. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2016.00363/full>
119. Camargo M, et al. High-throughput multi-omics for parasitic fingerprint mapping. *Curr Opin Infect Dis.* 2020;33(5):413–423. Available from: https://journals.lww.com/co-infectiousdiseases/fulltext/2020/10000/next_generation_sequencing_and_metagenomics_in.9.aspx
120. Chappell L, et al. Single-cell RNA-seq of Plasmodium-infected cells reveals host–parasite interactions. *Nat Commun.* 2020;11:3509. Available from: <https://www.nature.com/articles/s41467-020-17308-7>
121. Reid AJ, et al. Single-cell transcriptomics of malaria parasites and host response. *Cell.* 2018;173(7):1551–1566. Available from: [https://www.cell.com/cell/fulltext/S0092-8674\(18\)31227-4](https://www.cell.com/cell/fulltext/S0092-8674(18)31227-4)
122. Hoo R, et al. Systems biology approaches to malaria pathogenesis and immunity. *Trends Parasitol.* 2016;32(11):836–849. Available from: <https://www.sciencedirect.com/science/article/pii/S1471492216301275>
123. Quail MA, et al. Next-generation sequencing for parasite genome analysis. *Nat Rev Microbiol.* 2012;10(2):127–138. Available from: <https://www.nature.com/articles/nrmicro2715>
124. Lu Y, et al. Spatial transcriptomics reveals tissue-specific parasite-host interactions. *Nat Methods.* 2021;18(4):343–353. Available from: <https://www.nature.com/articles/s41592-021-01106-x>
125. Bunnik EM, et al. High-resolution proteomics of Plasmodium-infected erythrocytes. *Mol Cell Proteomics.* 2018;17(5):1005–1020. Available from: <https://www.mcponline.org/content/17/5/1005>
126. Vannier E, Krause PJ. Systems biology in parasitic diseases: Translational insights. *PLoS Pathog.* 2012;8(9):e1002975. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002975>
127. Llinás M, DeRisi JL. Computational modeling of parasite metabolic networks. *Curr Opin Microbiol.* 2017;39:1–7. Available from: <https://www.sciencedirect.com/science/article/pii/S1369527417300712>
128. Mwakalinga SB, et al. Point-of-care diagnostics for parasitic infections. *Diagnostics (Basel).* 2020;10(12):1022. Available from: <https://www.mdpi.com/2075-4418/10/12/1022>
129. White NJ, et al. Precision medicine and parasite biomarker-guided therapy. *Nat Rev Drug Discov.* 2014;13(6):455–471. Available from: <https://www.nature.com/articles/nrd4302>
130. Rijal S, et al. Multi-epitope vaccine design for parasitic infections guided by omics data. *Front Immunol.* 2019;10:2503. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.02503/full>
131. Schallig HDFH, Oskam L. Parasite-derived molecules as vaccine targets. *Expert Rev Vaccines.* 2013;12(10):1133–1147. Available from: <https://www.tandfonline.com/doi/full/10.1586/14760584.2013.835127>
132. Foth BJ, et al. CRISPR-Cas9 functional genomics in Plasmodium and other parasites. *Genome Res.* 2014;24(6):1036–1048. Available from: <https://genome.cshlp.org/content/24/6/1036>
133. McDermott JE, et al. Integration of multi-omics datasets to predict parasitic disease outcomes. *PLoS Comput Biol.* 2018;14(3):e1006013. Available from: <https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1006013>

134. Tetteh-Quarcoo PB, et al. Artificial intelligence in parasitology: Diagnostics and predictive modeling. *Parasite Immunol.* 2021;43(1):e12716. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/pim.12716>
135. McCall MB, et al. Emerging technologies in parasitic disease research. *Trends Parasitol.* 2019;35(11):895–910. Available from: <https://www.sciencedirect.com/science/article/pii/S147149221930089X>
136. Reid AJ, et al. Host–parasite co-evolution and molecular diversity. *PLoS Pathog.* 2017;13(8):e1006471. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006471>
137. Oliveira F, et al. Extracellular vesicles and parasite-host molecular communication. *Front Immunol.* 2020;11:578. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2020.00578/full>
138. Ghaffar K, et al. Point-of-care molecular diagnostics in parasitic diseases. *Diagnostics (Basel).* 2021;11(9):1613. Available from: <https://www.mdpi.com/2075-4418/11/9/1613>
139. Jäger A, et al. Single-cell multi-omics to map parasite fingerprints in host tissues. *Nat Commun.* 2022;13:1762. Available from: <https://www.nature.com/articles/s41467-022-29324-7>
140. McDermott JE, et al. Integration of multi-omics datasets to predict parasitic disease outcomes. *PLoS Comput Biol.* 2018;14(3):e1006013. Available from: <https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1006013>
141. Tetteh-Quarcoo PB, et al. Artificial intelligence in parasitology: Diagnostics and predictive modeling. *Parasite Immunol.* 2021;43(1):e12716. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/pim.12716>
142. Sampaio GL, et al. Proteomic profiling of Plasmodium-infected erythrocytes: Implications for disease severity. *Front Cell Infect Microbiol.* 2019;9:321. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2019.00321/full>
143. Bartholomeu DC, et al. Multi-omics integration for host–parasite interaction mapping. *Trends Parasitol.* 2017;33(12):973–985. Available from: [https://www.cell.com/trends/parasitology/fulltext/S1471-4922\(17\)30210-0](https://www.cell.com/trends/parasitology/fulltext/S1471-4922(17)30210-0)
144. de Souza W, Barrias ES. Extracellular vesicles in parasitic diseases: Insights into host modulation. *Front Cell Infect Microbiol.* 2019;9:146. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2019.00146/full>
145. Olivier M, et al. Leishmania-host cell interactions: Molecular insights and clinical relevance. *Trends Parasitol.* 2016;32(8):673–687. Available from: [https://www.cell.com/trends/parasitology/fulltext/S1471-4922\(16\)30089-6](https://www.cell.com/trends/parasitology/fulltext/S1471-4922(16)30089-6)
146. Petrescu AJ, et al. Metabolomic approaches to understanding host–parasite interactions in malaria. *Mol Biosyst.* 2018;14(6):1102–1113. Available from: <https://pubs.rsc.org/en/content/articlelanding/2018/mb/c8mb00134g>
147. Loke P, MacDonald AS. Helminth-mediated immune modulation: Implications for therapy. *Nat Rev Immunol.* 2017;17:387–400. Available from: <https://www.nature.com/articles/nri.2017.23>
148. Taylor S, et al. Host transcriptomic profiling in parasitic infections: Linking molecular signatures to disease. *Front Immunol.* 2020;11:594761. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2020.594761/full>
149. Machado FS, et al. Trypanosoma cruzi: Molecular mechanisms of pathogenesis and immunomodulation. *Curr Opin Microbiol.* 2019;52:20–27. Available from: <https://www.sciencedirect.com/science/article/pii/S1369527419300367>
150. World Health Organization. World malaria report 2022. Geneva: World Health Organization; 2022. Available from: <https://www.who.int/publications/i/item/9789240064898>
151. Alvar J, et al. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One.* 2012;7(5):e35671. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035671>
152. Sanchez L, et al. Molecular diagnostics for parasitic infections: Advancements and challenges. *Parasitol Res.* 2021;120:1373–1387. Available from: <https://link.springer.com/article/10.1007/s00436-021-07133-9>

153. Bhattacharyya S, et al. Proteomic fingerprints of helminth infections: Applications in diagnostics. *Proteomics Clin Appl*. 2018;12(7):e1700153. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/prca.201700153>
154. Pance A, et al. Extracellular vesicles in *Plasmodium falciparum* infection: Biomarker potential. *Front Cell Infect Microbiol*. 2020;10:529. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2020.00529/full>
155. Lustigman S, et al. Helminth genomics and host–parasite interactions. *Int J Parasitol*. 2019;49(5):367–380. Available from: <https://www.sciencedirect.com/science/article/pii/S0020751918302260>
156. Ghosh S, et al. Systems biology approaches to malaria pathogenesis. *Trends Parasitol*. 2018;34(11):897–909. Available from: [https://www.cell.com/trends/parasitology/fulltext/S1471-4922\(18\)30179-2](https://www.cell.com/trends/parasitology/fulltext/S1471-4922(18)30179-2)
157. Coakley G, et al. Extracellular vesicles from parasites: Mechanisms of host modulation. *Trends Parasitol*. 2015;31(12):601–609. Available from: [https://www.cell.com/trends/parasitology/fulltext/S1471-4922\(15\)00134-5](https://www.cell.com/trends/parasitology/fulltext/S1471-4922(15)00134-5)
158. National Center for Biotechnology Information (NCBI). Malaria parasite life cycle. In: *Malaria Life Cycle*. Bethesda (MD): National Library of Medicine; [cited year unknown]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK5951/figure/malaria_LifeCycle/
159. Andrade JM, et al. Integrative omics in Chagas disease: Linking molecular signatures to cardiomyopathy. *Front Cell Infect Microbiol*. 2021;11:676944. Available from: <https://www.frontiersin.org/articles/10.3389/fcimb.2021.676944/full>
160. Denny PW, et al. Molecular fingerprinting of *Plasmodium falciparum* for vaccine and drug development. *Front Immunol*. 2019;10:2550. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.02550/full>
161. Diray-Arce J, Conti MG, Petrova B, Kanarek N, Angelidou A, Levy O. Integrative metabolomics to identify molecular signatures of responses to vaccines and infections. *Metabolites*. 2020;10(12):492. Available from: <https://doi.org/10.3390/metabo10120492>
162. Mattoso-Barbosa AM, Sathler-Avelar R, Coelho-dos-Reis JGA, et al. Physiology and pathology of infectious diseases: The autoimmune hypothesis of Chagas disease. In: *Physiology and Pathology of Immunology*. London: InTech; 2017. Available from: <http://dx.doi.org/10.5772/intechopen.70342>